APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

TKI for Chronic Myeloid Leukemia

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global TKI for Chronic Myeloid Leukemia Industry Growth and Trends Forecast to 2032

Report ID 174041590127 December 2025111 pages

Choose your research edition.

Industry ResearchTKI for Chronic Myeloid Leukemia Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal TKI for Chronic Myeloid Leukemia Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal TKI for Chronic Myeloid Leukemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TKI for Chronic Myeloid Leukemia Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal TKI for Chronic Myeloid Leukemia Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global TKI for Chronic Myeloid Leukemia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TKI for Chronic Myeloid Leukemia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of TKI for Chronic Myeloid Leukemia include Apotex, Bristol Myers Squibb, Dr. Reddy's Laboratories, Eugia Pharma, Hetero, Lupin, Mylan, Novartis and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global TKI for Chronic Myeloid Leukemia market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The TKI for Chronic Myeloid Leukemia market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global TKI for Chronic Myeloid Leukemia market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to TKI for Chronic Myeloid Leukemia.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global TKI for Chronic Myeloid Leukemia market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

TKI for Chronic Myeloid Leukemia Market by Company

Apotex

Bristol Myers Squibb

Dr. Reddy's Laboratories

Eugia Pharma

Hetero

Lupin

Mylan

Novartis

Pfizer

Sawai Pharmaceutical

Sun Pharmaceuticals

Takeda Pharmaceuticals

Teva

Hansoh Pharmaceutical

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Suzhou Thery Pharmaceutical

Chia Tai Tianqing Pharmaceutical

TKI for Chronic Myeloid Leukemia Segment by Type

Imatinib

Ponatinib

Nilotinib

Flumatinib

Dasatinib

Bosutinib

Asciminib

Other

TKI for Chronic Myeloid Leukemia Segment by Application

Hospitals and clinics

Pharmacies

Others

TKI for Chronic Myeloid Leukemia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TKI for Chronic Myeloid Leukemia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TKI for Chronic Myeloid Leukemia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TKI for Chronic Myeloid Leukemia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of TKI for Chronic Myeloid Leukemia manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of TKI for Chronic Myeloid Leukemia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Imatinib Table 2. Major Company of Ponatinib Table 3. Major Company of Nilotinib Table 4. Major Company of Flumatinib Table 5. Major Company of Dasatinib Table 6. Major Company of Bosutinib Table 7. Major Company of Asciminib Table 8. Major Company of Other Table 9. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 11. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type (2021-2026) Table 12. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 13. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type (2021-2026) Table 14. Global TKI for Chronic Myeloid Leukemia Price by Type (2021-2026) & (US$/Unit) Table 15. Global TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 16. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type (2027-2032) Table 17. Global TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (US$ Million) Table 18. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type (2027-2032) Table 19. Global TKI for Chronic Myeloid Leukemia Price by Type (2027-2032) & (US$/Unit) Table 20. North America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 21. North America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 22. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 23. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 25. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 27. Latin America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 29. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (US$ Million) Table 30. TKI for Chronic Myeloid Leukemia Industry Trends Table 31. TKI for Chronic Myeloid Leukemia Industry Drivers Table 32. TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges Table 33. TKI for Chronic Myeloid Leukemia Industry Restraints Table 34. Global TKI for Chronic Myeloid Leukemia Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Company (2021-2026) Table 36. Global TKI for Chronic Myeloid Leukemia Sales by Company (2021-2026) & (K Units) Table 37. Global TKI for Chronic Myeloid Leukemia Sales Share by Company (2021-2026) Table 38. Global TKI for Chronic Myeloid Leukemia Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global TKI for Chronic Myeloid Leukemia Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global TKI for Chronic Myeloid Leukemia Major Company Production Sites and Headquarters Table 41. Global TKI for Chronic Myeloid Leukemia Company, Product Type & Application Table 42. Global TKI for Chronic Myeloid Leukemia Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global TKI for Chronic Myeloid Leukemia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global TKI for Chronic Myeloid Leukemia Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (K Units) Table 47. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Region (2021-2026) Table 48. Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (US$ Million) Table 49. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Region (2021-2026) Table 50. Global TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032) & (K Units) Table 52. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Region (2027-2032) Table 53. Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032) & (US$ Million) Table 54. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Region (2027-2032) Table 55. Global TKI for Chronic Myeloid Leukemia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global TKI for Chronic Myeloid Leukemia Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 58. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application (2021-2026) Table 59. Global TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 60. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application (2021-2026) Table 61. Global TKI for Chronic Myeloid Leukemia Price by Application (2021-2026) & (US$/Unit) Table 62. Global TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 63. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application (2027-2032) Table 64. Global TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (US$ Million) Table 65. Global TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application (2027-2032) Table 66. Global TKI for Chronic Myeloid Leukemia Price by Application (2027-2032) & (US$/Unit) Table 67. North America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 68. North America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 69. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 70. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 72. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 74. Latin America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 76. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (US$ Million) Table 77. Apotex Company Information Table 78. Apotex Business Overview Table 79. Apotex TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Apotex TKI for Chronic Myeloid Leukemia Product Portfolio Table 81. Apotex Recent Development Table 82. Bristol Myers Squibb Company Information Table 83. Bristol Myers Squibb Business Overview Table 84. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio Table 86. Bristol Myers Squibb Recent Development Table 87. Dr. Reddy's Laboratories Company Information Table 88. Dr. Reddy's Laboratories Business Overview Table 89. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio Table 91. Dr. Reddy's Laboratories Recent Development Table 92. Eugia Pharma Company Information Table 93. Eugia Pharma Business Overview Table 94. Eugia Pharma TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio Table 96. Eugia Pharma Recent Development Table 97. Hetero Company Information Table 98. Hetero Business Overview Table 99. Hetero TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Hetero TKI for Chronic Myeloid Leukemia Product Portfolio Table 101. Hetero Recent Development Table 102. Lupin Company Information Table 103. Lupin Business Overview Table 104. Lupin TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Lupin TKI for Chronic Myeloid Leukemia Product Portfolio Table 106. Lupin Recent Development Table 107. Mylan Company Information Table 108. Mylan Business Overview Table 109. Mylan TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Mylan TKI for Chronic Myeloid Leukemia Product Portfolio Table 111. Mylan Recent Development Table 112. Novartis Company Information Table 113. Novartis Business Overview Table 114. Novartis TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Novartis TKI for Chronic Myeloid Leukemia Product Portfolio Table 116. Novartis Recent Development Table 117. Pfizer Company Information Table 118. Pfizer Business Overview Table 119. Pfizer TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio Table 121. Pfizer Recent Development Table 122. Sawai Pharmaceutical Company Information Table 123. Sawai Pharmaceutical Business Overview Table 124. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 126. Sawai Pharmaceutical Recent Development Table 127. Sun Pharmaceuticals Company Information Table 128. Sun Pharmaceuticals Business Overview Table 129. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 131. Sun Pharmaceuticals Recent Development Table 132. Takeda Pharmaceuticals Company Information Table 133. Takeda Pharmaceuticals Business Overview Table 134. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 136. Takeda Pharmaceuticals Recent Development Table 137. Teva Company Information Table 138. Teva Business Overview Table 139. Teva TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Teva TKI for Chronic Myeloid Leukemia Product Portfolio Table 141. Teva Recent Development Table 142. Hansoh Pharmaceutical Company Information Table 143. Hansoh Pharmaceutical Business Overview Table 144. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 146. Hansoh Pharmaceutical Recent Development Table 147. Lunan Pharmaceutical Company Information Table 148. Lunan Pharmaceutical Business Overview Table 149. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 151. Lunan Pharmaceutical Recent Development Table 152. Qilu Pharmaceutical Company Information Table 153. Qilu Pharmaceutical Business Overview Table 154. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 156. Qilu Pharmaceutical Recent Development Table 157. CSPC Ouyi Pharmaceutical Company Information Table 158. CSPC Ouyi Pharmaceutical Business Overview Table 159. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 161. CSPC Ouyi Pharmaceutical Recent Development Table 162. Suzhou Thery Pharmaceutical Company Information Table 163. Suzhou Thery Pharmaceutical Business Overview Table 164. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 166. Suzhou Thery Pharmaceutical Recent Development Table 167. Chia Tai Tianqing Pharmaceutical Company Information Table 168. Chia Tai Tianqing Pharmaceutical Business Overview Table 169. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 171. Chia Tai Tianqing Pharmaceutical Recent Development Table 172. North America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 173. North America TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 174. North America TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 175. North America TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units) Table 176. North America TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Country (2027-2032) Table 177. North America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. North America TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026) & (US$ Million) Table 179. North America TKI for Chronic Myeloid Leukemia Market Share by Country (2021-2026) Table 180. North America TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. North America TKI for Chronic Myeloid Leukemia Market Share Forecast by Country (2027-2032) Table 182. Europe TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 183. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 184. Europe TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 185. Europe TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units) Table 186. Europe TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Country (2027-2032) Table 187. Europe TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Europe TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026) & (US$ Million) Table 189. Europe TKI for Chronic Myeloid Leukemia Market Share by Country (2021-2026) Table 190. Europe TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Europe TKI for Chronic Myeloid Leukemia Market Share Forecast by Country (2027-2032) Table 192. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 193. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 194. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 195. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units) Table 196. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Country (2027-2032) Table 197. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026) & (US$ Million) Table 199. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Share by Country (2021-2026) Table 200. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Share Forecast by Country (2027-2032) Table 202. Latin America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 203. Latin America TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 204. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 205. Latin America TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units) Table 206. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Country (2027-2032) Table 207. Latin America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. Latin America TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026) & (US$ Million) Table 209. Latin America TKI for Chronic Myeloid Leukemia Market Share by Country (2021-2026) Table 210. Latin America TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. Latin America TKI for Chronic Myeloid Leukemia Market Share Forecast by Country (2027-2032) Table 212. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 213. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 214. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share by Country (2021-2026) Table 215. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032) & (K Units) Table 216. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share Forecast by Country (2027-2032) Table 217. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026) & (US$ Million) Table 219. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Share by Country (2021-2026) Table 220. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Share Forecast by Country (2027-2032) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. TKI for Chronic Myeloid Leukemia Distributors List Table 225. TKI for Chronic Myeloid Leukemia Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. TKI for Chronic Myeloid Leukemia Image Figure 2. Global TKI for Chronic Myeloid Leukemia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TKI for Chronic Myeloid Leukemia Market Size (2021-2032) & (US$ Million) Figure 4. Global TKI for Chronic Myeloid Leukemia Sales (2021-2032) & (K Units) Figure 5. Imatinib Image Figure 6. Global Imatinib Sales YoY Growth (2021-2032) & (K Units) Figure 7. Ponatinib Image Figure 8. Global Ponatinib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Nilotinib Image Figure 10. Global Nilotinib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Flumatinib Image Figure 12. Global Flumatinib Sales YoY Growth (2021-2032) & (K Units) Figure 13. Dasatinib Image Figure 14. Global Dasatinib Sales YoY Growth (2021-2032) & (K Units) Figure 15. Bosutinib Image Figure 16. Global Bosutinib Sales YoY Growth (2021-2032) & (K Units) Figure 17. Asciminib Image Figure 18. Global Asciminib Sales YoY Growth (2021-2032) & (K Units) Figure 19. Other Image Figure 20. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 21. Global TKI for Chronic Myeloid Leukemia Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global TKI for Chronic Myeloid Leukemia Market Share by Type 2025 VS 2032 Figure 23. North America TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type in 2025 Figure 24. North America TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type in 2025 Figure 25. Europe TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type in 2025 Figure 26. Europe TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type in 2025 Figure 29. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type in 2025 Figure 30. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 TKI for Chronic Myeloid Leukemia Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Hospitals and clinics Image Figure 36. Global Hospitals and clinics Sales YoY Growth (2021-2032) & (K Units) Figure 37. Pharmacies Image Figure 38. Global Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 41. Global TKI for Chronic Myeloid Leukemia Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global TKI for Chronic Myeloid Leukemia Market Share by Application 2025 VS 2032 Figure 43. North America TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application in 2025 Figure 44. North America TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application in 2025 Figure 45. Europe TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application in 2025 Figure 46. Europe TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application in 2025 Figure 49. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application in 2025 Figure 50. Latin America TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Market Share in Value by Application in 2025 Figure 53. North America TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. North America TKI for Chronic Myeloid Leukemia Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America TKI for Chronic Myeloid Leukemia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America TKI for Chronic Myeloid Leukemia Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Europe TKI for Chronic Myeloid Leukemia Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe TKI for Chronic Myeloid Leukemia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe TKI for Chronic Myeloid Leukemia Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific TKI for Chronic Myeloid Leukemia Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Latin America TKI for Chronic Myeloid Leukemia Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America TKI for Chronic Myeloid Leukemia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America TKI for Chronic Myeloid Leukemia Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 70. Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa TKI for Chronic Myeloid Leukemia Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. TKI for Chronic Myeloid Leukemia Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. TKI for Chronic Myeloid Leukemia Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Imatinib
  • Ponatinib
  • Nilotinib
  • Flumatinib
  • Dasatinib
  • Bosutinib
  • Asciminib
  • Other
Applications
  • Hospitals and clinics
  • Pharmacies
  • Others
Companies covered
  • Apotex
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Hetero
  • Lupin
  • Mylan
  • Novartis
  • Pfizer
  • Sawai Pharmaceutical
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva
  • Hansoh Pharmaceutical
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Suzhou Thery Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global TKI for Chronic Myeloid Leukemia Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global TKI for Chronic Myeloid Leukemia Sales Estimates and Forecasts (2021-2032)
  5. 1.3 TKI for Chronic Myeloid Leukemia Market by Type
  6. 1.3.1 Imatinib
  7. 1.3.2 Ponatinib
  8. 1.3.3 Nilotinib
  9. 1.3.4 Flumatinib
  10. 1.3.5 Dasatinib
  11. 1.3.6 Bosutinib
  12. 1.3.7 Asciminib
  13. 1.3.8 Other
  14. 1.4 Global TKI for Chronic Myeloid Leukemia Market Size by Type
  15. 1.4.1 Global TKI for Chronic Myeloid Leukemia Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global TKI for Chronic Myeloid Leukemia Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global TKI for Chronic Myeloid Leukemia Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America TKI for Chronic Myeloid Leukemia Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe TKI for Chronic Myeloid Leukemia Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America TKI for Chronic Myeloid Leukemia Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 TKI for Chronic Myeloid Leukemia Industry Trends
  2. 2.2 TKI for Chronic Myeloid Leukemia Industry Drivers
  3. 2.3 TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges
  4. 2.4 TKI for Chronic Myeloid Leukemia Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by TKI for Chronic Myeloid Leukemia Revenue (2021-2026)
  2. 3.2 Global Top Players by TKI for Chronic Myeloid Leukemia Sales (2021-2026)
  3. 3.3 Global Top Players by TKI for Chronic Myeloid Leukemia Price (2021-2026)
  4. 3.4 Global TKI for Chronic Myeloid Leukemia Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global TKI for Chronic Myeloid Leukemia Major Company Production Sites & Headquarters
  6. 3.6 Global TKI for Chronic Myeloid Leukemia Company, Product Type & Application
  7. 3.7 Global TKI for Chronic Myeloid Leukemia Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global TKI for Chronic Myeloid Leukemia Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 TKI for Chronic Myeloid Leukemia Players Market Share by Revenue in 2025
  11. 3.8.3 2025 TKI for Chronic Myeloid Leukemia Tier 1, Tier 2, and Tier 3
4 TKI for Chronic Myeloid Leukemia Regional Status and Outlook
  1. 4.1 Global TKI for Chronic Myeloid Leukemia Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global TKI for Chronic Myeloid Leukemia Historic Market Size by Region
  3. 4.2.1 Global TKI for Chronic Myeloid Leukemia Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global TKI for Chronic Myeloid Leukemia Sales in Value by Region (2021-2026)
  5. 4.2.3 Global TKI for Chronic Myeloid Leukemia Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global TKI for Chronic Myeloid Leukemia Forecasted Market Size by Region
  7. 4.3.1 Global TKI for Chronic Myeloid Leukemia Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global TKI for Chronic Myeloid Leukemia Sales in Value by Region (2027-2032)
  9. 4.3.3 Global TKI for Chronic Myeloid Leukemia Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 TKI for Chronic Myeloid Leukemia by Application
  1. 5.1 TKI for Chronic Myeloid Leukemia Market by Application
  2. 5.1.1 Hospitals and clinics
  3. 5.1.2 Pharmacies
  4. 5.1.3 Others
  5. 5.2 Global TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 5.2.1 Global TKI for Chronic Myeloid Leukemia Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global TKI for Chronic Myeloid Leukemia Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global TKI for Chronic Myeloid Leukemia Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America TKI for Chronic Myeloid Leukemia Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe TKI for Chronic Myeloid Leukemia Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America TKI for Chronic Myeloid Leukemia Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Apotex
  2. 6.1.1 Apotex Company Information
  3. 6.1.2 Apotex Business Overview
  4. 6.1.3 Apotex TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Apotex TKI for Chronic Myeloid Leukemia Product Portfolio
  6. 6.1.5 Apotex Recent Developments
  7. 6.2 Bristol Myers Squibb
  8. 6.2.1 Bristol Myers Squibb Company Information
  9. 6.2.2 Bristol Myers Squibb Business Overview
  10. 6.2.3 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio
  12. 6.2.5 Bristol Myers Squibb Recent Developments
  13. 6.3 Dr. Reddy's Laboratories
  14. 6.3.1 Dr. Reddy's Laboratories Company Information
  15. 6.3.2 Dr. Reddy's Laboratories Business Overview
  16. 6.3.3 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio
  18. 6.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 6.4 Eugia Pharma
  20. 6.4.1 Eugia Pharma Company Information
  21. 6.4.2 Eugia Pharma Business Overview
  22. 6.4.3 Eugia Pharma TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio
  24. 6.4.5 Eugia Pharma Recent Developments
  25. 6.5 Hetero
  26. 6.5.1 Hetero Company Information
  27. 6.5.2 Hetero Business Overview
  28. 6.5.3 Hetero TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hetero TKI for Chronic Myeloid Leukemia Product Portfolio
  30. 6.5.5 Hetero Recent Developments
  31. 6.6 Lupin
  32. 6.6.1 Lupin Company Information
  33. 6.6.2 Lupin Business Overview
  34. 6.6.3 Lupin TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lupin TKI for Chronic Myeloid Leukemia Product Portfolio
  36. 6.6.5 Lupin Recent Developments
  37. 6.7 Mylan
  38. 6.7.1 Mylan Company Information
  39. 6.7.2 Mylan Business Overview
  40. 6.7.3 Mylan TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Mylan TKI for Chronic Myeloid Leukemia Product Portfolio
  42. 6.7.5 Mylan Recent Developments
  43. 6.8 Novartis
  44. 6.8.1 Novartis Company Information
  45. 6.8.2 Novartis Business Overview
  46. 6.8.3 Novartis TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Novartis TKI for Chronic Myeloid Leukemia Product Portfolio
  48. 6.8.5 Novartis Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Sawai Pharmaceutical
  56. 6.10.1 Sawai Pharmaceutical Company Information
  57. 6.10.2 Sawai Pharmaceutical Business Overview
  58. 6.10.3 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  60. 6.10.5 Sawai Pharmaceutical Recent Developments
  61. 6.11 Sun Pharmaceuticals
  62. 6.11.1 Sun Pharmaceuticals Company Information
  63. 6.11.2 Sun Pharmaceuticals Business Overview
  64. 6.11.3 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  66. 6.11.5 Sun Pharmaceuticals Recent Developments
  67. 6.12 Takeda Pharmaceuticals
  68. 6.12.1 Takeda Pharmaceuticals Company Information
  69. 6.12.2 Takeda Pharmaceuticals Business Overview
  70. 6.12.3 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  72. 6.12.5 Takeda Pharmaceuticals Recent Developments
  73. 6.13 Teva
  74. 6.13.1 Teva Company Information
  75. 6.13.2 Teva Business Overview
  76. 6.13.3 Teva TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Teva TKI for Chronic Myeloid Leukemia Product Portfolio
  78. 6.13.5 Teva Recent Developments
  79. 6.14 Hansoh Pharmaceutical
  80. 6.14.1 Hansoh Pharmaceutical Company Information
  81. 6.14.2 Hansoh Pharmaceutical Business Overview
  82. 6.14.3 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  84. 6.14.5 Hansoh Pharmaceutical Recent Developments
  85. 6.15 Lunan Pharmaceutical
  86. 6.15.1 Lunan Pharmaceutical Company Information
  87. 6.15.2 Lunan Pharmaceutical Business Overview
  88. 6.15.3 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  90. 6.15.5 Lunan Pharmaceutical Recent Developments
  91. 6.16 Qilu Pharmaceutical
  92. 6.16.1 Qilu Pharmaceutical Company Information
  93. 6.16.2 Qilu Pharmaceutical Business Overview
  94. 6.16.3 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  96. 6.16.5 Qilu Pharmaceutical Recent Developments
  97. 6.17 CSPC Ouyi Pharmaceutical
  98. 6.17.1 CSPC Ouyi Pharmaceutical Company Information
  99. 6.17.2 CSPC Ouyi Pharmaceutical Business Overview
  100. 6.17.3 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  102. 6.17.5 CSPC Ouyi Pharmaceutical Recent Developments
  103. 6.18 Suzhou Thery Pharmaceutical
  104. 6.18.1 Suzhou Thery Pharmaceutical Company Information
  105. 6.18.2 Suzhou Thery Pharmaceutical Business Overview
  106. 6.18.3 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  108. 6.18.5 Suzhou Thery Pharmaceutical Recent Developments
  109. 6.19 Chia Tai Tianqing Pharmaceutical
  110. 6.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 6.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 6.19.3 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  114. 6.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America TKI for Chronic Myeloid Leukemia Sales by Country
  2. 7.1.1 North America TKI for Chronic Myeloid Leukemia Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  4. 7.1.3 North America TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032)
  5. 7.2 North America TKI for Chronic Myeloid Leukemia Market Size by Country
  6. 7.2.1 North America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026)
  8. 7.2.3 North America TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe TKI for Chronic Myeloid Leukemia Sales by Country
  2. 8.1.1 Europe TKI for Chronic Myeloid Leukemia Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  4. 8.1.3 Europe TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032)
  5. 8.2 Europe TKI for Chronic Myeloid Leukemia Market Size by Country
  6. 8.2.1 Europe TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026)
  8. 8.2.3 Europe TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Country
  2. 9.1.1 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size by Country
  6. 9.2.1 Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America TKI for Chronic Myeloid Leukemia Sales by Country
  2. 10.1.1 South America TKI for Chronic Myeloid Leukemia Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  4. 10.1.3 South America TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032)
  5. 10.2 South America TKI for Chronic Myeloid Leukemia Market Size by Country
  6. 10.2.1 South America TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026)
  8. 10.2.3 South America TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Country
  2. 11.1.1 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa TKI for Chronic Myeloid Leukemia Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size by Country
  6. 11.2.1 Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa TKI for Chronic Myeloid Leukemia Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 TKI for Chronic Myeloid Leukemia Value Chain Analysis
  2. 12.1.1 TKI for Chronic Myeloid Leukemia Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 TKI for Chronic Myeloid Leukemia Production Mode & Process
  7. 12.2 TKI for Chronic Myeloid Leukemia Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 TKI for Chronic Myeloid Leukemia Distributors
  10. 12.2.3 TKI for Chronic Myeloid Leukemia Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst